Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model

Hanna Shevalye, Roman Stavniichuk, Weizheng Xu, Jie Zhang, Sergey Lupachyk, Yury Maksimchyk, Viktor R. Drel, Elizabeth Z. Floyd, Barbara Slusher, Irina G. Obrosova

Research output: Contribution to journalArticle

Abstract

Evidence for the important role for poly(ADP-ribose) polymerase (PARP) in the pathogenesis of diabetic nephropathy is emerging. We previously reported that PARP inhibitors counteract early Type 1 diabetic nephropathy. This study evaluated the role for PARP in kidney disease in long-term Type 1 diabetes. Control and streptozotocin-diabetic rats were maintained with or without treatment with the PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1, 2-diaza-benzo[de] anthracen-3-one (GPI- 15,427, Eisai Inc.), 30 mg kg -1 d-1, for 26 weeks after first 2 weeks without treatment. PARP activity in the renal cortex was assessed by Western blot analysis of poly(ADP-ribosyl)ated proteins. Urinary albumin, isoprostane, and 8-hydroxy-20-deoxyguanosine excretion, and renal concentrations of transforming growth factor-b1, vascular endothelial growth factor, soluble intercellular adhesion molecule-1, fibronectin, and nitrotyrosine were evaluated by ELISA, and urinary creatinine and renal lipid peroxidation products by colorimetric assays. PARP inhibition counteracted diabetes-associated increase in renal cortex poly(ADP-ribosyl)ated protein level. Urinary albumin, isoprostane, and 8- hydroxy-20-deoxyguanosine excretions and urinary albumin/creatinine ratio were increased in diabetic rats, and all these changes were at least partially prevented by GPI-15,427 treatment. PARP inhibition counteracted diabetes-induced renal transforming growth factor-β1, vascular endothelial growth factor, and fibronectin, but not soluble intercellular adhesion molecule-1 and nitrotyrosine, accumulations. Lipid peroxidation product concentrations were indistinguishable among control and diabetic rats maintained with or without GPI-15,427 treatment. In conclusion, PARP activation plays an important role in kidney disease in long-term diabetes. These findings provide rationale for development and further studies of PARP inhibitors and PARP inhibitor-containing combination therapies, for prevention and treatment of diabetic nephropathy.

Original languageEnglish (US)
Pages (from-to)1007-1014
Number of pages8
JournalBiochemical Pharmacology
Volume79
Issue number7
DOIs
StatePublished - Apr 1 2010
Externally publishedYes

Fingerprint

Poly(ADP-ribose) Polymerases
Kidney Diseases
Streptozocin
Rats
8-epi-prostaglandin F2alpha
Medical problems
Diabetic Nephropathies
Kidney
Albumins
Deoxyguanosine
Transforming Growth Factors
Intercellular Adhesion Molecule-1
Fibronectins
Vascular Endothelial Growth Factor A
Lipid Peroxidation
Creatinine
Therapeutics
Lipids
Type 1 Diabetes Mellitus
Assays

Keywords

  • Diabetic nephropathy
  • Oxidative-nitrosative stress
  • Poly(ADP-ribose) polymerase
  • Streptozotocin-diabetic rat
  • Transforming growth factor-β
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Pharmacology
  • Biochemistry

Cite this

Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. / Shevalye, Hanna; Stavniichuk, Roman; Xu, Weizheng; Zhang, Jie; Lupachyk, Sergey; Maksimchyk, Yury; Drel, Viktor R.; Floyd, Elizabeth Z.; Slusher, Barbara; Obrosova, Irina G.

In: Biochemical Pharmacology, Vol. 79, No. 7, 01.04.2010, p. 1007-1014.

Research output: Contribution to journalArticle

Shevalye, H, Stavniichuk, R, Xu, W, Zhang, J, Lupachyk, S, Maksimchyk, Y, Drel, VR, Floyd, EZ, Slusher, B & Obrosova, IG 2010, 'Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model', Biochemical Pharmacology, vol. 79, no. 7, pp. 1007-1014. https://doi.org/10.1016/j.bcp.2009.11.018
Shevalye, Hanna ; Stavniichuk, Roman ; Xu, Weizheng ; Zhang, Jie ; Lupachyk, Sergey ; Maksimchyk, Yury ; Drel, Viktor R. ; Floyd, Elizabeth Z. ; Slusher, Barbara ; Obrosova, Irina G. / Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. In: Biochemical Pharmacology. 2010 ; Vol. 79, No. 7. pp. 1007-1014.
@article{182522e330714b3ebaa448361b325cdb,
title = "Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model",
abstract = "Evidence for the important role for poly(ADP-ribose) polymerase (PARP) in the pathogenesis of diabetic nephropathy is emerging. We previously reported that PARP inhibitors counteract early Type 1 diabetic nephropathy. This study evaluated the role for PARP in kidney disease in long-term Type 1 diabetes. Control and streptozotocin-diabetic rats were maintained with or without treatment with the PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1, 2-diaza-benzo[de] anthracen-3-one (GPI- 15,427, Eisai Inc.), 30 mg kg -1 d-1, for 26 weeks after first 2 weeks without treatment. PARP activity in the renal cortex was assessed by Western blot analysis of poly(ADP-ribosyl)ated proteins. Urinary albumin, isoprostane, and 8-hydroxy-20-deoxyguanosine excretion, and renal concentrations of transforming growth factor-b1, vascular endothelial growth factor, soluble intercellular adhesion molecule-1, fibronectin, and nitrotyrosine were evaluated by ELISA, and urinary creatinine and renal lipid peroxidation products by colorimetric assays. PARP inhibition counteracted diabetes-associated increase in renal cortex poly(ADP-ribosyl)ated protein level. Urinary albumin, isoprostane, and 8- hydroxy-20-deoxyguanosine excretions and urinary albumin/creatinine ratio were increased in diabetic rats, and all these changes were at least partially prevented by GPI-15,427 treatment. PARP inhibition counteracted diabetes-induced renal transforming growth factor-β1, vascular endothelial growth factor, and fibronectin, but not soluble intercellular adhesion molecule-1 and nitrotyrosine, accumulations. Lipid peroxidation product concentrations were indistinguishable among control and diabetic rats maintained with or without GPI-15,427 treatment. In conclusion, PARP activation plays an important role in kidney disease in long-term diabetes. These findings provide rationale for development and further studies of PARP inhibitors and PARP inhibitor-containing combination therapies, for prevention and treatment of diabetic nephropathy.",
keywords = "Diabetic nephropathy, Oxidative-nitrosative stress, Poly(ADP-ribose) polymerase, Streptozotocin-diabetic rat, Transforming growth factor-β, Vascular endothelial growth factor",
author = "Hanna Shevalye and Roman Stavniichuk and Weizheng Xu and Jie Zhang and Sergey Lupachyk and Yury Maksimchyk and Drel, {Viktor R.} and Floyd, {Elizabeth Z.} and Barbara Slusher and Obrosova, {Irina G.}",
year = "2010",
month = "4",
day = "1",
doi = "10.1016/j.bcp.2009.11.018",
language = "English (US)",
volume = "79",
pages = "1007--1014",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model

AU - Shevalye, Hanna

AU - Stavniichuk, Roman

AU - Xu, Weizheng

AU - Zhang, Jie

AU - Lupachyk, Sergey

AU - Maksimchyk, Yury

AU - Drel, Viktor R.

AU - Floyd, Elizabeth Z.

AU - Slusher, Barbara

AU - Obrosova, Irina G.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Evidence for the important role for poly(ADP-ribose) polymerase (PARP) in the pathogenesis of diabetic nephropathy is emerging. We previously reported that PARP inhibitors counteract early Type 1 diabetic nephropathy. This study evaluated the role for PARP in kidney disease in long-term Type 1 diabetes. Control and streptozotocin-diabetic rats were maintained with or without treatment with the PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1, 2-diaza-benzo[de] anthracen-3-one (GPI- 15,427, Eisai Inc.), 30 mg kg -1 d-1, for 26 weeks after first 2 weeks without treatment. PARP activity in the renal cortex was assessed by Western blot analysis of poly(ADP-ribosyl)ated proteins. Urinary albumin, isoprostane, and 8-hydroxy-20-deoxyguanosine excretion, and renal concentrations of transforming growth factor-b1, vascular endothelial growth factor, soluble intercellular adhesion molecule-1, fibronectin, and nitrotyrosine were evaluated by ELISA, and urinary creatinine and renal lipid peroxidation products by colorimetric assays. PARP inhibition counteracted diabetes-associated increase in renal cortex poly(ADP-ribosyl)ated protein level. Urinary albumin, isoprostane, and 8- hydroxy-20-deoxyguanosine excretions and urinary albumin/creatinine ratio were increased in diabetic rats, and all these changes were at least partially prevented by GPI-15,427 treatment. PARP inhibition counteracted diabetes-induced renal transforming growth factor-β1, vascular endothelial growth factor, and fibronectin, but not soluble intercellular adhesion molecule-1 and nitrotyrosine, accumulations. Lipid peroxidation product concentrations were indistinguishable among control and diabetic rats maintained with or without GPI-15,427 treatment. In conclusion, PARP activation plays an important role in kidney disease in long-term diabetes. These findings provide rationale for development and further studies of PARP inhibitors and PARP inhibitor-containing combination therapies, for prevention and treatment of diabetic nephropathy.

AB - Evidence for the important role for poly(ADP-ribose) polymerase (PARP) in the pathogenesis of diabetic nephropathy is emerging. We previously reported that PARP inhibitors counteract early Type 1 diabetic nephropathy. This study evaluated the role for PARP in kidney disease in long-term Type 1 diabetes. Control and streptozotocin-diabetic rats were maintained with or without treatment with the PARP inhibitor 10-(4-methyl-piperazin-1-ylmethyl)-2H-7-oxa-1, 2-diaza-benzo[de] anthracen-3-one (GPI- 15,427, Eisai Inc.), 30 mg kg -1 d-1, for 26 weeks after first 2 weeks without treatment. PARP activity in the renal cortex was assessed by Western blot analysis of poly(ADP-ribosyl)ated proteins. Urinary albumin, isoprostane, and 8-hydroxy-20-deoxyguanosine excretion, and renal concentrations of transforming growth factor-b1, vascular endothelial growth factor, soluble intercellular adhesion molecule-1, fibronectin, and nitrotyrosine were evaluated by ELISA, and urinary creatinine and renal lipid peroxidation products by colorimetric assays. PARP inhibition counteracted diabetes-associated increase in renal cortex poly(ADP-ribosyl)ated protein level. Urinary albumin, isoprostane, and 8- hydroxy-20-deoxyguanosine excretions and urinary albumin/creatinine ratio were increased in diabetic rats, and all these changes were at least partially prevented by GPI-15,427 treatment. PARP inhibition counteracted diabetes-induced renal transforming growth factor-β1, vascular endothelial growth factor, and fibronectin, but not soluble intercellular adhesion molecule-1 and nitrotyrosine, accumulations. Lipid peroxidation product concentrations were indistinguishable among control and diabetic rats maintained with or without GPI-15,427 treatment. In conclusion, PARP activation plays an important role in kidney disease in long-term diabetes. These findings provide rationale for development and further studies of PARP inhibitors and PARP inhibitor-containing combination therapies, for prevention and treatment of diabetic nephropathy.

KW - Diabetic nephropathy

KW - Oxidative-nitrosative stress

KW - Poly(ADP-ribose) polymerase

KW - Streptozotocin-diabetic rat

KW - Transforming growth factor-β

KW - Vascular endothelial growth factor

UR - http://www.scopus.com/inward/record.url?scp=77449124908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77449124908&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2009.11.018

DO - 10.1016/j.bcp.2009.11.018

M3 - Article

C2 - 19945439

AN - SCOPUS:77449124908

VL - 79

SP - 1007

EP - 1014

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -